As Eliquis Sales Lag, Bristol/Pfizer Take Action
This article was originally published in The Pink Sheet Daily
Executive Summary
The oral anticoagulant generated just $12 million in sales in its first full quarter since it launched in the U.S., lower than expected. Bristol will increase investment in the brand to drive growth.